AstraZeneca turns again to UK's Silence in renewed RNAi push

AstraZeneca and Silence Therapeutics, which first partnered in 2007, will team up to develop RNA interference drug candidates for diseases of the liver, heart, kidney and lung.

AstraZeneca turns again to UK's Silence in renewed RNAi push
AstraZeneca and Silence Therapeutics, which first partnered in 2007, will team up to develop RNA interference drug candidates for diseases of the liver, heart, kidney and lung.